Aurora Cannabis Inc. (NYSE:ACB) Announces Plan to Launch Proprietary Softgel Capsules

Aurora Cannabis Inc. (NYSE:ACB) has announced that shipments for its proprietary cannabis softgel capsules have begun with exports expected to kick off in the beginning of next year. The company, which announced in October that it has been granted the sales license by Health Canada for the softgel capsules is already making big strides towards getting the product available in the market for its clients.

Story continues below


The company subcontracted a renowned softgel manufacturer, Capcium, in which it has about 20% ownership, to develop pharmaceutical-grade capsules in its Quebec facility. The modern Aurora Vie manufacturing facility is expected to produce a minimum of 1.4 million capsules weekly.

The high production is expected to fulfill the demand of the high-volume, high-margin, smoke-free product which will be available to both domestic legal markets across the border.

The capsule, believed to be the smallest cannabis-based capsule, is designed to be easy to digest and is uniquely color-coded to be easily identifiable between the various varieties. This is equally important in safeguarding users’ health and safety.

Product types

Aurora is originally unveiling a 4 cannabis softgel product variety. The softgels will be packaged in bottles containing 30 capsules each. A single bottle will be retailing at a standard price of $45. The softgels come with a dosage-controlled format that will guide pharmacists and users to administer precise doses.

Among the four product types set to be launched, the following three will be for the medical market; Aurora Indica Softgels: 8-10 mg/pill of THC,Aurora Sativa Softgels: 8-10 mg/pill of THC and the Aurora CBD Softgels: 8-10 mg/pill of CBD. The BC consumer market will only have the Aurora Liquid Gels: 8-10 mg/pill of CBD which can be bought over the counter without prescription.

Management’s statement

Terry Booth, CEO of Aurora in a statement regarding the softgel products praised his company’s efforts in making the anticipated products available to both patients and recreational consumers. For his part, Shane Morris of the Product Development and Regulatory Affairs affirmed that the company was prepared to meet the product’s demand as plans were underway to scale up production in the coming weeks.

An ad to help with our costs